Search
7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE
go.drugbank.com/drugs/DB07512ExperimentalCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesRiferminogene pecaplasmid
go.drugbank.com/drugs/DB06394InvestigationalRiferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Norethynodrel
go.drugbank.com/drugs/DB09371ApprovedA synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combin...
Categories: Hormonal Contraceptives for Systemic UseTalsupram
go.drugbank.com/drugs/DB09191ExperimentalIt was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
TAK-754
go.drugbank.com/drugs/DB17850InvestigationalDeveloped by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]
Afimkibart
go.drugbank.com/drugs/DB18718InvestigationalIt is being investigated for ulcerative colitis.
Diethanolamine
go.drugbank.com/drugs/DB20489InvestigationalDiethanolamine is under investigation in clinical trial NCT02499549 (Two Treatment Regimens of Cocamide DEA Lotion for Head Lice). Diethanolamine has a monoisotopic molecular weight of 105.08 Da.
Xelaglifam
go.drugbank.com/drugs/DB21598InvestigationalXelaglifam is under investigation in clinical trial NCT04982705 (IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics). Xelaglifam has a monoisotopic molecular weight of 501.2 Da.